- Home
- INCY vs UDR Comparison
INCY vs UDR Comparison
Compare INCY & UDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- UDR
- Stock Information
- Founded
- INCY 1991
- UDR 1972
- Country
- INCY United States
- UDR United States
- Employees
- INCY N/A
- UDR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- UDR Real Estate Investment Trusts
- Sector
- INCY Health Care
- UDR Real Estate
- Exchange
- INCY Nasdaq
- UDR Nasdaq
- Market Cap
- INCY 13.0B
- UDR 13.7B
- IPO Year
- INCY 1993
- UDR N/A
- Fundamental
- Price
- INCY $70.20
- UDR $40.42
- Analyst Decision
- INCY Hold
- UDR Hold
- Analyst Count
- INCY 20
- UDR 13
- Target Price
- INCY $72.75
- UDR $45.92
- AVG Volume (30 Days)
- INCY 1.5M
- UDR 1.8M
- Earning Date
- INCY 07-29-2025
- UDR 07-30-2025
- Dividend Yield
- INCY N/A
- UDR 4.26%
- EPS Growth
- INCY N/A
- UDR N/A
- EPS
- INCY 0.10
- UDR 0.36
- Revenue
- INCY $4,413,226,000.00
- UDR $1,705,220,000.00
- Revenue This Year
- INCY $13.48
- UDR $1.05
- Revenue Next Year
- INCY $10.37
- UDR $3.49
- P/E Ratio
- INCY $723.63
- UDR $112.54
- Revenue Growth
- INCY 17.13
- UDR 2.11
- 52 Week Low
- INCY $53.56
- UDR $36.61
- 52 Week High
- INCY $83.95
- UDR $47.55
- Technical
- Relative Strength Index (RSI)
- INCY 55.91
- UDR 45.16
- Support Level
- INCY $67.17
- UDR $40.40
- Resistance Level
- INCY $71.29
- UDR $40.76
- Average True Range (ATR)
- INCY 1.51
- UDR 0.60
- MACD
- INCY 0.06
- UDR 0.03
- Stochastic Oscillator
- INCY 74.23
- UDR 45.16
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About UDR UDR Inc.
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized; and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.